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ABSTRACT
Host CD4T cells that survive sublethal or even lethal preconditioning regimens can participate in the process
of hematopoietic stem cell graft rejection, particularly when the transplantations are performed across a major
histocompatibility complex (MHC) class II barrier. To enhance donor marrow engraftment, we tested the
efficacy of a small synthetic cyclic heptapeptide, 802-2 (CNSNQIC), which was designed to closely mimic the
CD4 domain 1 CC= surface loop, theoretically involved in CD4/MHC class II complex oligomerization and
subsequent CD4 T-cell activation. Previously, this peptide was found to have inhibitory activity in murine
models for CD4 T cell–dependent graft-versus-host disease and skin allograft rejection. Herein, we used the
MHC class II-–disparate bm12¡ B6-CD45.1 sublethal irradiation transplantation model to test the possibility
that the 802-2 peptide could enhance the engraftment of donor T cell–depleted bone marrow (ATBM).
Sublethally irradiated B6-CD45.1 mice that received bm12 ATBM in combination with the 802-2 peptide
demonstrated increased donor marrow cell engraftment as compared with mice that received ATBM alone;
this suggests that the 802-2 peptide may be useful as an immunomodulating agent to overcome MHC class II
mismatch barriers in hematopoietic stem cell transplantation.
© 2005 American Society for Blood and Marrow Transplantation
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TNTRODUCTION
Allogeneic blood and bone marrow transplanta-
ion (BMT) can be a potentially curative treatment for
everal malignant and nonmalignant hematologic dis-
ases, although several major obstacles may hamper an
verall successful outcome. These complications in-
lude graft failure, opportunistic infections, relapse of
alignancy, and either acute or chronic graft-versus-
ost disease (GVHD). In the case of GVHD, mature
lloreactive donor T cells in the graft can mediate
onsiderable tissue damage and lead to signiﬁcant
orbidity and mortality [1,2]. Conversely, donor T
ells are important for ensuring engraftment by tar-
eting residual host elements, can mount antitumor
ffects, and can stave off opportunistic infections after
ransplantation [3]. To reconcile these conﬂicting
oles of the donor T cells, BMT strategies must be c
B&MTeveloped in an effort to retain the positive capabilities
hile reducing or controlling the deleterious effects.
raft failure remains an important part of the equation
n consideration for improved BMT outcomes, as evi-
enced in the recent development of nonmyeloablative
onditioning regimens to reduce the incidence of trans-
lant-related mortality and to promote hematopoietic
himerism. In this case, although the approach holds
reat promise for making the transplantation option
vailable to a much broader range of patients, it has
nfortunately also led to a signiﬁcantly higher risk of
raft rejection [4-6].
The elucidation of the detailed interactive nature
f antigenic peptide/major histocompatibility complex
MHC) molecules on antigen-presenting cells with
-cell receptor/CD4 complexes on helper CD4 T
ells and of additional co-receptors has established a
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9oundation for developing novel approaches to medi-
te graft acceptance [7]. Modalities for achieving allo-
raft tolerance have included blocking the ligation of
D40/CD40 ligand molecules on the surface of den-
ritic antigen-presenting cells and blocking the liga-
ion of CD28/B7-1 and B7-2 molecules on T cells,
ither directly by use of antibodies or by use of soluble
ytotoxic T lymphocyte antigen 4 (CTLA-4) mole-
ules [8,9]. Other promising therapeutic targets aim at
isrupting the putative antigen-induced oligomeriza-
ion process among CD4 molecules, thus rendering
he T cells anergic [10].
We have previously used a small synthetic cyclic
eptapeptide, 802-2 (CNSNQIC), which was designed
o closely mimic the CD4 domain 1 CC= surface loop,
heoretically involved in CD4/MHC class II complex
ligomerization and subsequent CD4 T-cell activa-
ion [11]. This peptide was found to have an inhibitory
ffect in MHC-mismatched murine models on the
evelopment of CD4 T cell–dependent GVHD and
kin allograft rejection [11] and could inhibit the de-
elopment of CD4 T cell–mediated autoimmunity
n models for experimental allergic encephalomyelitis
12]. Herein we used the MHC class II–disparate bm12
B6-CD45.1 sublethal irradiation BMT model to test
he possibility that the 802-2 peptide could enhance the
ngraftment of T cell–depleted bone marrow (ATBM)
y preventing the residual host CD4 T cell–mediated
ejection of donor hematopoietic stem cells. Recipient
ice were exposed to 800 cGy of irradiation and
dministered phosphate-buffered saline (PBS), a sin-
le intravenous dose of 802-2 peptide, or anti-CD4
onoclonal antibody (mAb) at the time of BMT.
onor-host chimerism was assessed 1 to 2 months
fter transplantation by ﬂow cytometric analysis of
pleen and/or lymph node cells. Both 802-2 peptide–
reated and anti-CD4 mAb–treated recipients exhib-
ted enhanced donor lymphoid engraftment, with
0% to 80% donor chimerism, as compared with 20%
o 30% for the PBS-treated control mice. Further-
ore, engraftment of donor hematopoietic progenitor
ells in the spleens of recipients was assessed by a
-day colony-forming unit–granulocyte macrophage
CFU-GM) assay, in which 802-2 peptide–treated an-
mals yielded enhanced numbers of donor colonies.
aken together, these results suggest that the 802-2
eptide may be useful as an immunomodulating agent
o overcome MHC class II mismatch barriers in
MT.
ATERIALS AND METHODS
ice
MHC class II mutant B6.C-H2bm12 (bm12) mice
which express the CD45.2 marker) were purchased
rom the Jackson Laboratory (Bar Harbor, ME), and B
806-Ly5.2 mice (which actually express the CD45.1
arker and are referred to herein as B6-CD45.1 mice
o avoid confusion in the nomenclature) were pur-
hased from the National Cancer Institute (Bethesda,
D). Male bm12 mice, 7 to 12 weeks of age, were
sed as bone marrow donors, and male B6-CD45.1
ice, 7 to 10 weeks of age, were used as recipients.
ice were kept in a sterile environment in microiso-
ator cages at all times and were provided with acidi-
ed water and autoclaved food.
edia
PBS solution supplemented with 0.1% bovine se-
um albumin (BSA; Sigma Chemical, St. Louis, MO)
as used for all in vitro manipulations of the donor
one marrow cells and lymphocytes. For intravenous
njection, all cells were resuspended in PBS. RPMI
640 medium (Mediatech, Herndon, VA) was used for
ll in vitro assays, supplemented with 10% fetal calf
erum (Atlanta Biologicals, Norcross, GA), 2 mmol/L
lutamine, 50 U/mL penicillin, 50 mg/mL streptomy-
in, and 0.05 mmol/L 2-mercaptoethanol (Mediatech).
ethocult M3230 (Stemcell Technologies, Vancou-
er, BC, Canada) methylcellulose medium was used
or all in vitro colony assays, supplemented with 50
/mL interleukin 3 (Biosource International, Cama-
illo, CA), 2 mmol/L glutamine, 50 U/mL penicillin,
nd 50 mg/mL streptomycin (Mediatech).
02-2 Peptide
The cyclized 802-2 peptide (CNSNQIC), de-
igned as previously described [11], was synthesized
n an Applied Biosystems 430A peptide synthesizer
Foster City, CA) and a model 9050 Pepsynthesizer
lus (Perspective Biosystems, Cambridge, MA) by
olid-phase synthesis with a standard F-moc strategy.
he purity of the ﬁnal product was assessed by ana-
ytical reverse-phase and matrix-assisted laser desorp-
ion/ionization time-of-ﬂight mass spectrometry. The
eptide was reconstituted in PBS (2.5 mg/mL) for
njection into mice.
rradiation
All recipient mice received appropriate sublethal
otal body irradiation exposures of 650 to 900 cGy by
sing a Mark-I-68A cesium 137 source (143 cGy/min;
L Shepherd, San Francisco, CA).
onoclonal Antibodies
Ascites ﬂuid for anti-Thy1.2 (J1j.10, rat immuno-
lobulin [Ig]M; American Type Culture Collection
Manassas, VA] TIB184) [13] and anti-CD4 (GK1.5,
at IgG2b; American Type Culture Collection TIB-
07) [14] mAbs was generated in our laboratory from
ntraperitoneal (IP) injection of the hybridomas into
ALB/c nu/nu mice (National Cancer Institute). Goat
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Bnti-mouse IgG antibody was purchased from Cap-
el-Organon Teknika (Durham, NC), and FcR
locking mAb [15]was purchased from Pharmingen
San Diego, CA). Surface phenotype was analyzed
y dual-color immunoﬂuorescence by using the fol-
owing ﬂuorescein isothiocyanate (FITC)–conjugated
nd/or R-phycoerythrin (PE)–conjugated anti-mouse
Abs, purchased from Pharmingen: rat anti-CD45.1
clone A20-1.7), rat anti-Thy1.2 (CD90; clone 30-
12), rat anti-CD4 (clone RM4-5), rat anti-CD8a
clone 53-6.7), rat anti-CD45R/B220 (clone RA3-
B2), mouse anti-CD45.2 mAb (clone 104), and, as a
egative control, rat IgG2ak.
ell Preparations
Bone marrow cells were prepared from the fe-
urs and tibiae of donor mice by ﬂushing with PBS/
SA. To prepare anti-Thy1.2 mAb–treated (T cell–
epleted) bone marrow (ATBM), cells were incubated
ith J1j.10 mAb (1:100 dilution) and guinea pig com-
lement (1:20) for 45 minutes at 37°C and were
ashed 3 times. ATBM cells were counted and resus-
ended at 5  107/mL in PBS. This treatment re-
ulted in a donor cell population deﬁcient of Thy1.2
ells, as determined by immunoﬂuorescence/ﬂow cy-
ometry.
one Marrow Engraftment
In an adaptation of the bone marrow engraftment
odel used by Vallera et al. [16], recipient mice were
xposed to an appropriate level of sublethal total body
rradiation 4 to 6 hours before injection of donor
TBM cells. Mice were then given a 0.2-mL injection
f PBS (IV), 802-2 peptide (0.5 mg IV), or anti-CD4
Ab (1:100 dilution of GK1.5 ascites ﬂuid, 25 g,
P, 2). Chimerism was analyzed at 1 and 2 months
fter transplantation. For presensitization experi-
ents, recipient B6-CD45.1 mice were injected IP
ith 2  107 bm12 splenocytes 14 days before irradi-
tion and BMT.
himerism Phenotyping
FITC–anti-CD45.1 and PE–anti-CD45.2 mAb,
long with T- or B-cell differentiation antigens, were
sed to evaluate the phenotype and the degree of
himerism in the spleens (at 1 month) or in the spleens
nd lymph nodes (at 2 months) of bm12 ¡ B6-
D45.1 recipients. For analysis, single-cell suspen-
ions (1  106 cells per sample) were incubated and
ashed with PBS/0.1% BSA and 0.05% NaN3 (ﬂuo-
escence-activated cell-sorter buffer). Cell samples in
volume of 100 L were initially incubated with 25
L of anti-Fc receptor mAb for 10 minutes at 4°C to
revent nonspeciﬁc Fc binding before further incuba-
ion with phenotypic mAb [15]. Samples were ana-
yzed on an XL-MCL ﬂow cytometer (Beckman r
B&MToulter, Miami, FL): a minimum of 104 cells was
nalyzed for each determination.
ssay for Hematopoietic Progenitors and
henotypic Analysis
The CFU-GM assay was performed according
o a modiﬁcation of a method described previously
17,18]. Brieﬂy, splenocytes were collected and pooled
rom 3 recipient mice per treatment group on day 5
fter transplantation, 1  105 cells per group were
lated in triplicate 35-mm culture dishes in 1 mL of
ethocult media, and cultures were maintained at
7°C in 7% carbon dioxide for 6 days. Cell aggregates
hat contained 30 cells (CFU-GM) were scored as
ndividual colonies on day 6 of culture, and after a
urther 2 to 4 days of culture, 6 to 9  102 cell
ggregates were extracted from the methylcellulose
nd pooled from each treatment group, yielding
pproximately 2  105 cells. These cells were then
henotyped by dual-color ﬂow cytometry with PE–
nti-CD45.1 and FITC–anti-CD45.2 mAb to deter-
ine the origin of the CFU-GM cells.
tatistical Analyses
The mean percentage expressions of CD45.2 (do-
or) or CD45.1 (recipient) on cells in the experimen-
al populations were compared with each other for
igniﬁcance by the unpaired t test.
ESULTS
adiation Dose Titration Effect on
onor Engraftment
Dose titration experiments were performed to de-
ermine the optimal level of preconditioning radiation
xposure of B6-CD45.1 recipients to ensure maxi-
um residual host resistance to the engraftment of
 107 donor bm12 ATBM cells. Flow cytometric
nalysis of splenocytes was used to measure the per-
entage of donor chimerism at 30 days after BMT.
ice that weighed 25 to 29 g and were exposed to
ublethal 750 to 800 cGy of radiation exhibited ap-
roximately 20% donor chimerism (Figure 1). Recip-
ent mice that received radiation doses 850 cGy
xhibited a signiﬁcant increase (65%; P  .014) in
onor chimerism. It was also found that the weight of
he mice played an important role in determining the
ptimal radiation dose. For mice that weighed 22 to
5 g, similar donor cell engraftment levels (approxi-
ately 65%) were attainable at an exposure of 800
Gy (data not shown). Therefore, proper irradiation
oses were chosen and adjusted for the weights of the
ecipient mice in each experiment.
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9ffect of 802-2 Peptide on Donor Mononuclear
ell Engraftment
To investigate the effect of the 802-2 peptide on
nhancement of donor bone marrow engraftment, sub-
ethally irradiated (800 cGy) B6-CD45.1 mice trans-
lanted with 107 bm12 ATBM cells received an injec-
igure 1. Radiation dose titration effect on donor engraftment in
he MHC class II–mismatched bm12 ¡ B6-CD45.1 strain combi-
ation. B6-CD45.1 mice (n  3-5) were exposed to irradiation with
he indicated dosage and underwent transplantation with allogeneic
m12 ATBM (107 cells). Splenocytes from recipients were analyzed
or donor chimerism on day 30 after BMT by ﬂow cytometry with
ITC–anti-CD45.1 (expressed by recipient) and PE–anti-CD45.2
expressed by donor) mAb. The data are presented as the mean
ercentage of chimerism  SD and are from 1 representative ex-
eriment of 2 performed.
igure 2. Effect of 802-2 peptide on splenic donor mononuclear
ell engraftment 30 days after BMT. B6-CD45.1 mice (n  3-5)
ere exposed to 800 cGy of irradiation and underwent transplan-
ation with allogeneic bm12 ATBM (107 cells). Recipients were
reated on day 0 with PBS, 802-2 peptide (0.5 mg), or anti-CD4
Ab. Mononuclear cells from recipient spleens were analyzed for
onor/recipient chimerism on day 30 after BMT by ﬂow cytometry
ith FITC–anti-CD45.1 and PE–anti-CD45.2 mAb. The donor
xpressions in the 802-2 peptide (76.5%) and anti-CD4 mAb
80.1%) treatment groups were signiﬁcantly higher than in the PBS
ontrol group (38.3%; P  .001). The data (mean  SD) are frommrepresentative experiment of 2 performed.
82ion of PBS (0.2 mL IV), 802-2 peptide (0.5 mg; 0.2
L; IV), or anti-CD4 mAb (25 g; 0.2 mL; IP). Flow
ytometric analysis 30 days after BMT indicated
8.3% donor engraftment of donor origin CD45.2
ononuclear cells in the spleens of the PBS control
roup, whereas both the 802-2 peptide and anti-CD4
Ab treatment groups had an approximately 2-fold
ncrease of donor cell engraftment (76.5% and 80.1%,
espectively; P  .001; Figure 2).
At 72 days after BMT, 57.2% of the splenocytes in
he PBS group were of donor origin, whereas the
ngraftment level reached 73.5% and 75.0% (P 
03), respectively, in the 802-2 and anti-CD4 mAb
roups (Figure 3). These results suggested that a sin-
le injection of 802-2 peptide analogue at the time of
ransplantation resulted in signiﬁcant enhancement of
onor engraftment in the lymphoid compartment.
ffect of 802-2 Peptide on Donor
-Cell Reconstitution
To asses the effect of the 802-2 peptide on the
egree of donor CD4 and CD8 T-cell subset recon-
titution in bm12 ATBM-transplanted B6-CD45.1 re-
ipients after PBS, 802-2, or anti-CD4 mAb treat-
ent, splenocytes were initially analyzed by ﬂow
ytometry on day 30 after BMT. At this time point,
here was a signiﬁcant increase in the CD4 T-cell
onor compartment after 802-2 peptide treatment com-
ared with the PBS-treated group (from 36% to 56%,
espectively; P .002; Figure 4A). A similarly signiﬁcant
ncrease was observed in mice that received anti-CD4
igure 3. Splenic donor mononuclear cell engraftment 72 days
fter BMT. B6-CD45.1 mice underwent transplantation with bm12
TBM and were treated as described in Figure 2. Mononuclear
ells from recipient spleens (n  3-5) were analyzed for donor
himerism on day 72 after BMT. The donor expressions in the
02-2 peptide (73.5%) and anti-CD4 mAb (75.0%) treatment
roups were signiﬁcantly higher than in the PBS control group
38.3%; P  .03). The data (mean  SD) represent the mean of 2
xperiments.Ab treatment (58%). Among the CD8 T cells, there
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Bas a moderate, but only marginally signiﬁcant (P 
09), increase in the donor compartment in the 802-2
59.0%) and anti-CD4 (54.4%) groups compared with
hat of the PBS control (43.4%; Figure 4B).
On day 72 after BMT, the increases in the levels of
he donor-derived CD4 and CD8 T-cell populations
ere still apparent in the spleens of the respective 802-
–treated (61% and 64%) and anti-CD4 mAb–treated
65% and 66%) groups compared with the PBS group
igure 4. Donor CD4 and CD8 T-cell reconstitution in spleens
0 days after BMT. B6-CD45.1 mice underwent transplantation
ith bm12 ATBM and were treated as described in Figure 2. CD4
nd CD8 T cells from recipient spleens (n  3-5) were analyzed
or donor chimerism and T-cell phenotype on day 30 after BMT.
, The donor expressions in the 802-2 peptide (56%) and anti-
D4 mAb (57.8%) treatment groups were signiﬁcantly different
rom that of the PBS control group (36.0%; P  .002). B, The
onor CD8 T-cell values in the 802-2 peptide (59%) and
nti-CD4 mAb (54.4%) treatment groups were marginally sig-
iﬁcantly different from that of the PBS control group (43.4%;
 .09). The data (mean  SD) are from 1 representative
xperiment of 2 performed.50% and 58%; data not shown). This later time point p
B&MTlso afforded an adequate opportunity to examine
ymph node reconstitution, and it was found that
he donor-derived CD4 T cells increased signiﬁ-
antly (P  .039) in the 802-2–treated and anti-
D4 mAb–treated recipients (81% and 76%,
espectively) compared with the PBS-treated group
61%; Figure 5A). Donor CD8 T-cell chimerism
as also signiﬁcantly increased (P  .002) from
7.6% in the PBS group to 81.6% and 74.4% in the
02-2–treated and anti-CD4–treated groups, re-
pectively (Figure 5B).
igure 5. Donor CD4 and CD8 T-cell reconstitution in lymph
odes 72 days after BMT. B6-CD45.1 mice underwent transplan-
ation with bm12 ATBM and were treated as described in Figure 2.
D4 and CD8 T cells from recipient (n  3-5) lymph nodes
ere analyzed for donor chimerism on day 72 after BMT by ﬂow
ytometry. A, The donor-derived CD4 T-cell values in the 802-2
eptide (81%) and anti-CD4 mAb treatment (76%) groups were
igniﬁcantly higher than in the PBS control group (61%; P  .04).
, Donor CD8 T-cell chimerism was also signiﬁcantly increased
P  .002), from 57.6% in the PBS group to 81.6% and 74.4% in
he 802-2–treated and anti-CD4–treated groups, respectively. The
ata (mean  SD) are from 1 representative experiment of 2
erformed.
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9ematopoietic Progenitor Cell Engraftment in
02-2 Peptide–Treated Mice
The potential to form granulocyte-macrophage
olonies (CFU-GM) within the ﬁrst week after donor
TBM transplantation is a major sign of successful
ngraftment [17,18]. Thus, the effect of 802-2 peptide
dministration on the enhancement of bm12 donor–
erived CFU-GM was investigated. Splenocytes were
ooled from 3 B6-CD45.1 mice per treatment group
0.2 mL of PBS IV, 0.5 mg of 802-2 in 0.2 mL IV, and
5 g of anti-CD4 mAb in 0.2 mL IP) on day 5 after
MT and cultured for 6 days in semisolid methylcellu-
ose medium to develop the CFU-GM colonies. In-
reased numbers of CFU-GM colonies were formed in
plenocyte cultures from the 802-2 peptide–treated
2.4-fold) and the anti-CD4 mAb–treated (4.1-fold)
roups in comparison to the PBS control group (P 
001; Figure 6). The CFU-GM progenitor cells were
urther analyzed for donor/host origin by 2-color ﬂow
ytometry with FITC–anti-CD45.1 and PE–anti-
D45.2 mAb. Colonies were found to be 90% do-
or origin in all of the treatment groups (data not
hown). Overall, the results of the CFU-GM assay
upported the broad augmentation of donor hemato-
oietic cell engraftment at the early post-BMT stages
fter a single injection of the 802-2 peptide.
ffect of 802-2 Peptide on Donor Marrow
ngraftment in Presensitized Recipients
In human BMT, prior blood transfusions and par-
ty may presensitize the patients to donor histocom-
igure 6. Effect of 802-2 peptide on CFU-GM colony formation.
6-CD45.1 mice underwent transplantation with bm12 ATBM and
ere treated as described in Figure 2. On day 5 after BMT, spleno-
ytes were pooled from 3 B6-CD45.1 mice per treatment group,
lated in triplicate in semisolid methylcellulose media, and cultured
or 6 days. Colonies that contained30 CFU-GM cells were scored
s positive. Increased numbers of colonies were formed in spleno-
yte cultures from the 802-2 peptide–treated (2.4-fold) and the
nti-CD4 mAb–treated (4.1-fold) groups in comparison to the PBS
ontrol group (P  .001). The results are from 1 representative
xperiment of 3 performed.atibility antigens and thereby increase the risk of p
84raft rejection [19]. To assess the capacity of the 802-2
eptide to inhibit host resistance to engraftment in
his more aggressive type of situation, B6-CD45.1
ice were presensitized with 2  107 bm12 spleno-
ytes by IP immunization 14 days before transplanta-
ion. On the day of transplantation, the recipient B6-
D45.1 mice were irradiated (800 cGy) and injected
ith 107 bm12 ATBM cells. Preliminary experiments
ith a single treatment of 802-2 peptide or anti-CD4
Ab on the day of transplantation (previously found
ffective in naive recipients, as in Figure 2) resulted in
nly minimal enhancement of donor chimerism in
he spleen, as measured on day 30 (data not shown).
n an attempt to maximize the effect of the peptide,
n subsequent presensitization experiments, recipi-
nt mice were given 802-2 (0.5 mg IV) on each of
ays 0 to 3 after BMT. This treatment schedule
aused a signiﬁcant increase in donor chimerism
ompared with the PBS-treated control mice (62%
ersus 15%; P  .007; Figure 7). It is interesting to
ote that only weak and insigniﬁcant (P  .05)
nhancement of engraftment was observed in mice
reated with multiple doses of anti-CD4 mAb (days
-3; 29% donor chimerism). Thus, in the case of
resensitized recipient mice, treatment with the
02-2 peptide proved to be solely effective in over-
iding the host memory CD4 T-cell response and
nhancing donor engraftment.
igure 7. Effect of 802-2 peptide on donor chimerism in presen-
itized recipients. B6-CD45.1 mice were presensitized (IP) with 2
07 bm12 splenocytes 14 days before irradiation exposure (800 cGy)
nd transplantation with bm12 ATBM (107 cells). Recipients were
reated daily from day 0 to 3 with PBS, 802-2 peptide (0.5 mg), or
nti-CD4 mAb. Donor chimerism was analyzed 30 days after BMT
y ﬂow cytometry with FITC–anti-CD45.1 and PE–anti-CD45.2
Ab. This treatment schedule caused a signiﬁcant increase in donor
himerism in the 802-2–treated group (62%) compared with the
BS-treated control mice (15%; P  .007). The data (mean  SD)
re from 1 representative experiment (n  5 mice per group) of 2
erformed.
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BISCUSSION
In this article, we have described a novel approach
hat uses a small cyclic heptapeptide, which is able to
isrupt the function of the CD4 molecule during the
ctivation process and speciﬁcally inhibit activated al-
oreactive CD4 T cells. This approach provides a
ore targeted therapy as part of a posttransplantation
mmunomodulating treatment regimen to promote
ematopoietic stem cell engraftment. The 802-2 pep-
ide was able to signiﬁcantly enhance donor marrow
ngraftment across an MHC class II barrier in suble-
hally irradiated recipients, in which residual host
D4 T cells can mediate graft rejection [16]. The
evels of donor chimerism achieved after a single in-
ection of 802-2 peptide treatment at the time of
ransplantation in nonsensitized recipients were nearly
quivalent to those reached with pan-depleting anti-
D4 mAb treatment.
The inhibition of CD4T-cell responses by treat-
ent of recipient mice with mAb directed against the
D4 molecule effectively decreases the incidence of
VHD and graft rejection after transplantation [20].
owever, mAb treatment for other diseases has been
ssociated with several problems in the clinical setting.
ong-term treatment of autoimmune patients with
arying anti-CD4 mAbs has resulted in general im-
unosuppression and an increased risk of opportunis-
ic infections [21,22]. Shorter-term treatments with
Ab may be more promising from a safety point of
iew because they allow the CD4 compartment to
ecover more quickly [23]. In addition, some labora-
ories have reported the inability of anti-CD4 mAb
reatments to inhibit memory T-cell responses [24-
7]. Murine antibodies have also been found to induce
uman anti-mouse immunoglobulin responses that
an limit the effectiveness and prolonged application
f these treatments [28].
In contrast, the 802-2 peptide confers several ad-
antages over anti-CD4 mAb. The peptide does not
eem to be immunogenic and has failed to generate
ntibody responses upon repeated injection in mice
unpublished data). Most importantly, there was no
igniﬁcant diminution in the size of the CD4 T-cell
ubset within days after 802-2 administration, and the
D4 T cells were fully functional, as evidenced by
heir capacity to respond to both recall antigens and
hird-party alloantigens [12]. Perhaps the most signif-
cant ﬁnding, with relevance to the human BMT sit-
ation, was that 802-2, in contrast to mAb, was also
apable of inhibiting the anti-donor activity of presen-
itized CD4 host T cells (Figure 7). The half-life
etention of 802-2 in the serum of mice is approxi-
ately 12 minutes, although it is unclear how long the
eptide may be concentrated in the peripheral lym-
hoid system (unpublished data, 2004). This poten-
ially short window of efﬁcacy might account for the m
B&MTbservation that multiple treatments over the ﬁrst 3 days
fter transplantation were much more effective than a
ingle dose in the inhibition of presensitized host T-cell
ejection of the marrow graft (Figure 7).
Pretransplantation immunization of recipients via
lood transfusion may increase the incidence of mar-
ow graft rejection, and this issue has always been a
rimary concern for patients with aplastic anemia
29,30]. In leukemia patients receiving allogeneic
MT, the development of graft failure varies depend-
ng on several factors, including the type of precondi-
ioning and immunosuppression, the strength of the
LA and non-HLA histocompatibility antigen dis-
arities involved, presensitization of the recipients,
nd sex mismatch in female recipients [31-33]. In
ddition, the advent of approaches involving T-cell
epletion of bone marrow to prevent GVHD signiﬁ-
antly increased the incidence of graft failure with
LA-identical transplant situations [33,34] and with
atched unrelated marrow donors [35], theoretically
ecause of the lack of donor alloreactive responses to
etard the residual host immune elements responsible
or rejection. In recent years, the development of non-
yeloablative approaches with reduced overall trans-
lant-related toxicity to the recipients has gained much
nterest, but it also increases the risk of graft failure [4-6].
ecause 1 of the main aims of these reduced-intensity
onditioning regimens is to reach a state of clinical
olerance by allowing establishment of a mixed chimeric
mmune system [36], the targeting of alloreactive T
ells from either the donor or host compartment
ould seem to be an essential component. Theoreti-
ally, the use of the 802-2 peptide analogue, together
ith a nonmyeloablative approach, could optimize the
nduction of tolerance through inhibition of all allo-
eactive CD4 T cells and markedly reduce the inci-
ence of morbidity and mortality in the early post-
ransplantation period.
In the clinical setting for HLA-identical transplan-
ations, marrow rejection seems to be mediated pri-
arily by CD8 T cells [37]. In HLA-mismatched
ituations, both humoral and cellular mechanisms may
ause rejection, the latter predominantly because of
D4 and CD8 T cells directed to MHC class II
nd class I antigens, respectively [38,39]. The distinc-
ive role of T-cell subsets in graft failure has also
een clearly demonstrated experimentally in MHC-
ismatched strain combinations, including the bm12
B6-CD45.1 model used in this study [16]. In light
f the potential importance of host presensitization to
raft rejection mediated by both T-cell subsets, it is
igniﬁcant that the 802-2 peptide analogue was able to
ubstantially block the response of the primed host to
HC class II–disparate donor marrow (Figure 7).
Related investigations with the 802-2 peptide in
urine models for experimental allergic encephalo-
yelitis, skin graft rejection, and GVHD have dem-
985
o
C
i
w
r
c
p
t
p
d
t
c
T
T
l
o
p
e
a
a
t
b
d
v
o
l
i
m
a
a
f
i
(
t
c
o
C
m
a
s
o
a
s
p
r
q
b
t
C
i
t
a
t
h
s
w
c
r
l
p
s
m
e
r
a
s
p
s
A
o
w
g
I
R
1
G. Varadi et al.
9nstrated inhibitory effects on the development of
D4 T cell–mediated disease [11,12]. Furthermore,
n the experimental allergic encephalomyelitis study, it
as found that 802-2 could affect secondary T-cell
esponses, thus suggesting that even memory T cells
ould be disrupted in their activation process by the
eptide [12]. On the basis of computer modeling of
he CD4/MHC class II interactions, it has been pro-
osed that the CDR3-CC= loop region on the ﬁrst
omain of the CD4 molecule forms a binding pocket
hat allows for oligomerization of CD4/MHC class II
omplexes; this, in turn, enhances the cross-linking of
-cell receptors necessary for T-cell activation [10].
he 802-2 peptide is a structural mimic of the CC=
oop and is thus hypothesized to interfere with stable
ligomerization. Recent preliminary experiments sup-
ort this notion in that the presence of 802-2 during
xposure of CD4 T-cell receptor transgenic cells to
B-cell line presenting appropriate antigen results in
signiﬁcant decrease of synapse formation and p56lck
yrosine kinase activity, whereas fyn activity seems to
e undiminished (Sarma and Korngold, unpublished
ata, 2004). In addition, this disturbance in the acti-
ation cascade is thought to then lead either to a form
f anergy or to apoptosis of the responding T cell, the
atter indicated by the observation of a signiﬁcant
ncrease of poly(adenosine diphosphate ribose) poly-
erase (PARP) cleavage and caspase 3 activity 3 days
fter exposure to antigen and 802-2.
It is not yet understood whether the mechanism of
ction of 802-2 is the same for memory T cells as it is
or naive T cells in the presence of antigen. However,
t is clear from the presensitized recipient experiments
Figure 7) that 802-2 treatment in vivo is more effec-
ive than anti-CD4 mAb at inhibition of memory T
ells, and this would suggest that the mechanisms
f action are indeed different between the 2 agents.
hace et al. [25] investigated the inability of anti-CD4
Ab to delete interleukin 2R CD4 T cells in vivo
nd suggested that the antibody mediates a negative
ignal through the CD4-p56lck molecule which can be
verridden by T-cell receptor engagement. However,
s stated previously, 802-2 may operate by reducing
ynapse formation and causing an imbalance between
56lck and fyn signaling; the imbalance leads to dis-
uption of the T-cell activation process and subse-
uent anergy or apoptosis. This mechanism may thus
e operative for both naive and memory T cells.
In this study, we hypothesize that the 802-2 pep-
ide largely inhibits the residual host alloreactive
D4 T cells that are being activated (or reactivated,
n the case of presensitized cells) early after transplan-
ation, thus rendering them incapable of mounting an
ttack against donor hematopoietic stem cells and
heir differentiated progeny. With the short serum
alf-life of the 802-2 peptide in vivo, it is reasonable to
uggest the possibility that, if administered only 1
86ithin the ﬁrst week of transplantation, the peptide
ould speciﬁcally inhibit both host-versus-graft–
eactive and GVHD-reactive CD4 T cells while
eaving the remaining nonalloreactive CD4 T-cell
opulations intact for subsequent development of re-
ponses to opportunistic infections or potential leuke-
ic relapse.
In summary, the 802-2 peptide seems to be an
ffective agent for the prevention of marrow graft
ejection as a result of MHC class II incompatibilities
fter a reduced-intensity conditioning regimen and, as
uch, may serve as a platform for the development of
hase I studies to test its efﬁcacy in the clinical BMT
etting.
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